Cortexyme Company

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.


Investors

Total Funding: 225000000
Headquarters: South San Francisco, California, United States
Funding Status: IPO
Employee Number: 11-50
Estimated Revenue: $10M to $50M
Investment Stage: N/A
Last Funding Type: Post-IPO Equity
Number Of Exists: N/A
Technology: Gene therapy
Investor Type: N/A
Last Funding Date: 2019
Investors Number: 13
Founded Date: 2012
Industry: Biotechnology, Health Care, Medical, Pharmaceutical